# **Mapping the Data Ecosystem of Psychedelic-Assisted Therapy: Institutional Standards, Real-World Evidence, and Distributed Clinical Intelligence**

The therapeutic landscape for psychedelic-assisted interventions is currently undergoing a structural transformation from a disparate collection of subterranean practices and early-stage academic inquiries into a regulated, evidence-based medical and spiritual framework. This evolution is fundamentally driven by the aggregation and analysis of data from a multitude of sources, each possessing unique epistemological strengths and limitations. The evidentiary standard required for the formal medicalization of substances such as psilocybin, MDMA, and LSD remains functionally aligned with traditional pharmaceutical regulations, yet the profound subjective nature of the psychedelic experience necessitates a more comprehensive "mosaic of data systems" than has been required for conventional psychiatric medications.1 This report examines the diverse data repositories, standardization protocols, and analytical frameworks currently defining the field, with a particular focus on the integration of institutional randomized controlled trials (RCTs), real-world evidence (RWE) from clinical practice, and grassroots citizen science initiatives.

## **Institutional Standards and the Regulatory Evidence Paradigm**

The U.S. Food and Drug Administration (FDA) serves as the primary arbiter of clinical data legitimacy for psychedelic drug development. The agency’s 2023 draft guidance on psychedelic drugs emphasizes that sponsors must provide exhaustive information regarding chemistry, manufacturing, and controls (CMC) to ensure the purity, strength, and identification of both investigational drug substances and finished products.3 This requirement is particularly complex when dealing with botanical sources, such as psilocybin mushrooms or iboga root bark, where consistent quality must be maintained across multiple batches to prevent confounding variables in clinical outcomes.5 Furthermore, the FDA requires rigorous non-clinical safety studies, including an evaluation of binding activity at the 5-HT2B receptor subtype, which is associated with heart valvulopathy in humans—a critical safety concern for drugs intended for chronic or repeated administration.3

Data standardization is the cornerstone of regulatory approval. The adoption of Clinical Data Interchange Standards Consortium (CDISC) standards is increasingly mandatory for successful Investigational New Drug (IND) and New Drug Application (NDA) submissions.8 These standards facilitate the exchange of complex clinical, molecular, and real-world data, providing a unified format that the FDA utilizes for its regulatory evaluation of health products.8 Within this framework, the Research Electronic Data Capture (REDCap) system has emerged as the preferred tool for managing data in multi-site clinical trials and longitudinal surveys.11 REDCap’s metadata-driven workflow enables researchers to design customizable clinical forms while maintaining strict adherence to HIPAA and 21 CFR Part 11 requirements, ensuring the integrity and security of participant information.12

| Standard / Tool | Regulatory Function | Clinical Application |
| :---- | :---- | :---- |
| **CDISC SDTM** | Data Tabulation | Standardizing raw clinical trial data for submission to regulatory agencies.15 |
| **CDISC ADaM** | Analysis Dataset | Structuring data for statistical analysis and primary endpoint validation.9 |
| **Dataset JSON** | Exchange Format | Enhancing the transfer of complex genomic and molecular datasets between sponsors and regulators.8 |
| **REDCap** | Data Capture | Secure, metadata-driven management of case report forms and participant surveys.11 |
| **FDA CMC** | Quality Control | Rigorous identification and purity testing for botanical and synthetic compounds.3 |

The internal data architecture of contemporary psychedelic studies often utilizes a "triple masking" approach, where participants, care providers, and investigators remain unaware of group allocation to mitigate the profound impact of expectancy bias.17 However, the phenomenon of "functional unblinding"—where participants correctly guess their condition due to the unmistakable psychoactive effects—remains a significant challenge to the internal validity of psychedelic RCTs.18 Analysts suggest that the entire estimated effect size of these interventions could potentially be accounted for by these confounds, necessitating the use of active placebos, blinding questionnaires, and central blinded raters to maintain the rigor of causal inferences.18

## **Real-World Evidence and Measurement-Based Care Platforms**

The limitations of traditional RCTs—specifically their slow pace, rigid inclusion criteria, and detachment from naturalistic clinical settings—have led to an increased emphasis on Real-World Evidence (RWE). Platforms such as Osmind, Maya Health, and Althea have positioned themselves as the operational backbone of the legal psychedelic ecosystem, integrating specialized Electronic Health Records (EHR) with outcome-tracking capabilities.23 These platforms are designed to bridge the gap between academic research and clinical practice, allowing practitioners to collect and analyze patient-reported outcomes (PRO) in real-time.

Osmind, for example, is tailored for ketamine-assisted psychotherapy (KAP) and Spravato clinics, offering over 30 validated rating scales and automated symptom alerts with smart thresholds.24 Its data-driven approach turns subjective experiences into tangible data, facilitating Measurement-Based Care that can be used to justify treatment reimbursement from insurance providers.24 Maya Health utilizes a similar model, leveraging academic research to capture lived experiences and inform public policy and clinical best practices.26 These platforms often collaborate with non-profits such as Unlimited Sciences or Bendable Therapy to conduct IRB-approved studies that collect demographic data, mental health histories, and validated clinical scale scores like the PHQ-8 and GAD-7.26

Althea provides a crucial infrastructure for the regulated psilocybin programs in Oregon and Colorado. The platform assists facilitators in maintaining compliance with state-specific mandates, such as the collection of de-identified data for health outcomes and session details.29 Althea’s platform automatically invites participants to complete evidence-based questionnaires before and after sessions, establishing professional credibility grounded in participant feedback.30 A key component of this intake process is the Psychedelic Preparedness Scale (PPS), which measures a client’s readiness for therapy across four pillars: knowledge, expectation management, intention, and psychological stability.32

| Platform | Core Value | Specialized Features |
| :---- | :---- | :---- |
| **Osmind** | Clinical Efficiency | KAP chart templates, REMS submission, and 30+ rating scales.24 |
| **Maya Health** | Data Advocacy | Real-world data platform for practitioners and researchers.26 |
| **Althea** | Compliance | Oregon/Colorado regulatory documentation and outcomes tracking.23 |
| **Albert Labs** | RWE Development | Large-scale clinical development for KRN-101 therapy.34 |
| **Woven Science** | Accessibility | Ecosystem focused on healthcare accessibility and dissolvable psilocybin compounds.26 |

The accumulation of data from these platforms is essential for understanding the "patient journey" beyond the limited window of controlled trials. This real-world perspective reveals how psychedelic therapy functions when participants maintain standard psychiatric medications or present with complex comorbidities—factors that are typically used as exclusion criteria in traditional research.35 Analysis of RWE from the T21 medical cannabis database, which serves as a model for the psychedelic field, indicates that naturalistic datasets can be much larger and possess greater temporal sensitivity than all RCTs to date combined.37

## **Practitioner Networks and the Clinical Intelligence "Hive Mind"**

The Psychedelic Practitioners Network (PPN) represents a novel model of decentralized data aggregation that prioritizes the collaborative intelligence of individual providers. The PPN Research Portal is conceptualized as a "Wisdom Trust" where practitioners anonymize and contribute clinical data to benchmark their own success against the community.39 This model addresses a critical failure in the emerging market: the fact that thousands of valuable data points regarding dosages, protocols, and outcomes are currently lost in isolated therapist notes.39

The PPN architecture, specifically version 3.1, features an institutional-standard data architecture designed for future absorption by larger entities, such as pharmaceutical companies or academic researchers.39 A unique component of this system is the "AI Neural Engine," which allows users to search protocols based on granular criteria like demographics, conditions, and treatment failures.39 The inclusion of data on "what went wrong" is a significant departure from standard reporting practices, where practitioner ego often leads to a focus solely on successful outcomes.39 By capturing failures and adverse events in real-time, the network acts as an "early warning system" that can identify issues like a contaminated batch of medication or a previously unknown drug interaction risk months before official warnings can be issued.1

Technically, the PPN utilizes a "Zero-Knowledge Architecture" to manage HIPAA and PHI liabilities. Patient information is encrypted locally on the practitioner's device, ensuring that the central platform holds no keys to decrypt personally identifiable information.39 This "Local-First" privacy model allows for the tracking of unique patient identifiers without exposing identities to the cloud, effectively shielding practitioners from data breach liability while still enabling the drill-down functionality necessary for protocol analysis.39

| PPN Portal Feature | Operational Benefit | Analytical Impact |
| :---- | :---- | :---- |
| **Neural Copilot** | Safety Guardrails | Flags risky doses for patients on SSRIs before the session occurs.39 |
| **Affinity Binding Hover** | Pharmacological Detail | Provides instant receptor-level info (e.g., 5-HT1A roles in mood).39 |
| **Audit Logs** | Regulatory Defense | Cryptographically hashes doses and outcomes for forensic-grade audit trails.39 |
| **Tough Case Library** | Protocol Discovery | Offers evidence-based roadmaps for high-anxiety non-responders.39 |
| **Benchmark Dashboard** | Quality Assurance | Allows therapists to calibrate PHQ-9 score drops against global averages.39 |

The monetization model for such networks typically employs a "Give-to-Get" loop, where initial access is free for practitioners who contribute a set number of anonymized records per month.39 Once the database reaches a critical mass—estimated at 10,000+ records—the aggregated insights themselves become the primary product, which can be licensed to pharmaceutical researchers or Drug-Drug Interaction (DDI) database providers.39

## **Citizen Science and the Microdosing Data Initiative**

Microdosing—the intermittent use of sub-perceptual amounts of psychedelics—presents a unique analytical challenge because it occurs predominantly outside the purview of traditional clinical oversight. Data collection in this subfield has relied almost exclusively on citizen science initiatives and crowdsourced repositories. Dr. James Fadiman’s work has been foundational, utilizing a "Self-Study" protocol that requests daily notes and overviews of effects over ten four-day cycles.41 His research has cataloged improvements in conditions ranging from depression and anxiety to stuttering and menstrual pain, though he emphasizes that the effects are often idiosyncratic and can exacerbate certain conditions, such as anxiety or color blindness.42

The most prominent data collection tool in this space is the microdose.me study, conducted via the Quantified Citizen mobile app. This ongoing study has engaged over 33,000 participants from 84 countries, making it the largest observational study of its kind.45 Participants are asked to complete a comprehensive battery of psychometric tests at baseline and at various timepoints over a 3-month period, including the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) and the Quick Inventory of Depressive Symptomatology (QIDS).45

| Outcome Category | Timescale | Key Measures Used |
| :---- | :---- | :---- |
| **Acute** | Daily (Thursday) | PANAS mood schedule, Visual Analogue Scales (VAS) for energy/creativity.47 |
| **Post-Acute** | Weekly (Sunday) | STAI-T anxiety trait inventory, Social Connectedness Scale (SCS).47 |
| **Accumulative** | Monthly (Baseline/W5) | Ryff’s Psychological Well-being (RPWB), Big Five Personality (B5).47 |
| **Cognitive** | Monthly (Baseline/W5) | Cognitive Performance Score (CPS) across spatial span and planning tasks.47 |

Despite the massive volume of self-reported data, analysis in this field is consistently complicated by the "expectancy effect." A 2021 study in *eLife* utilized a "self-blinding" protocol where participants prepared their own opaque microdose and placebo capsules, tracking their guesses alongside their outcomes.47 The findings revealed that while microdosers saw significant improvements in well-being and life satisfaction, those taking a placebo saw nearly identical benefits, suggesting that anecdotal reports are largely driven by positive psychological expectations.49 This research illustrates a critical evolution in data gathering: the ability to implement high-quality placebo controls in decentralized settings at a fraction of the cost of clinical trials.49

## **Specialized Registries for Ibogaine and Noribogaine**

Research into ibogaine and its primary metabolite, noribogaine, focuses on their unique "anti-addictive" properties and their potential to treat traumatic brain injury (TBI). Because ibogaine is often accessed through clinics in jurisdictions like Mexico, Brazil, or South Africa, the Global Ibogaine Patient Survey (operating via the RAY—Research Accelerated by You platform) serves as the primary centralized location for real-world evidence.51

The survey investigates the acute subjective effects of ibogaine, such as visions and panoramic life recall, and correlates these with long-term abstinence from problematic opioid consumption.54 Analytical findings indicate that treatment responders—those who achieve sustained abstinence for six months or more—rate their experiences as significantly more spiritually meaningful and report higher levels of post-treatment psychological well-being.54 The study also highlights the rapid resolution of withdrawal symptoms, which typically occurs within 34 hours of the initial dose.54

Ibogaine's pharmacological profile is notably complex, involving interactions with opioid receptors, nicotinic acetylcholine receptors, and the sigma-2 receptor.55 This "polypharmacology" is believed to be responsible for the drug's ability to "rewire" damaged circuitry in the prefrontal cortex, which is particularly relevant for military veterans suffering from chronic TBI and PTSD.57 A 2024 Stanford University study documented dramatic improvements in cognitive function and emotional regulation among special operations veterans, with no instances of serious cardiotoxic side effects when the treatment was properly medically supervised.53

| Clinical Feature | Observation in Ibogaine Registry | Relevance for Drug Development |
| :---- | :---- | :---- |
| **Withdrawal Relief** | Rapid onset (1-3 hours); full resolution by 34 hours.54 | Transitions patients from dependence to abstinence.54 |
| **Craving Suppression** | 50% reported reduction; 25% sustained for 3+ months.54 | Key endpoint for FDA OUD drug development programs.61 |
| **Abstinence Rate** | 30% never used opioids again; 41% abstinent at 6 months.54 | Demonstrates high efficacy relative to conventional MAT.54 |
| **Pharmacokinetics** | Storage in adipose tissues; protracted noribogaine release.55 | Requires long-term monitoring for safety and durability.55 |
| **Receptor Affinity** | Strongest at sigma-2, SERT, and DAT.55 | Directs the search for non-hallucinogenic psychoplastogen analogs.62 |

The Ibogaine Patient Survey aims to provide robust data that could influence policy decisions regarding the drug's regulatory status in the United States.51 By documenting safety concerns and outcome nuances in real-world settings, researchers hope to establish evidence-based protocols for screening, administration, and aftercare, potentially opening pathways for legal, supervised therapeutic use.51

## **Integrative Data Models in Neurodegenerative Research**

The convergence of psychedelic research and neurodegenerative studies is exemplified by the work of Dr. Laurie Mischley, particularly her Modifiable Variables in Parkinsonism (MVP) Study. While not exclusively focused on psychedelics, her research provides a sophisticated template for integrating diverse data streams to understand disease progression. The MVP study has tracked over 3,000 participants for more than a decade, identifying dozens of "modifiable variables"—such as financial status, exercise frequency, and nutritional choices—that correlate with fewer Parkinson's symptoms over time.65

Dr. Mischley’s PRO-PD (Patient-Reported Outcomes in Parkinson's Disease) scale is a patient-centered, continuous measure of disease severity that is stratifiable by symptom.68 This tool is crucial for disease-modification research, as traditional measurement systems often exhibit "floor effects" that make them insensitive in newly diagnosed individuals.70 One of the most critical findings from this dataset is the significant impact of social health; participants who report being lonely rate their symptoms twice as severely as those who are socially connected, and loneliness is associated with a 43% faster rate of disease progression.66

| Clinical Variable | Impact on Progression / Severity | Data Source |
| :---- | :---- | :---- |
| **Exercise** | More days/week correlates with fewer reported symptoms.66 | MVP Study (PRO-PD App).66 |
| **Social Connection** | Loneliness is the single greatest predictor of rapid progression.72 | MVP Study (N=1,500 over 5 years).72 |
| **Diet (Antioxidants)** | Berries and leafy greens associated with slower progression.67 | MVP Summary Report (2024).67 |
| **Diet (Dopamine Interference)** | Dairy and meat consumption linked to increased diagnosis risk.66 | Traditional Epidemiology (Multi-country).74 |
| **Supplements** | CoQ10, fish oil, and glutathione show therapeutic potential.21 | MVP Observational Data.21 |

Dr. Mischley’s "ParK-9" project further expands the boundaries of data collection by utilizing canine scent detection to identify Parkinsonism from earwax samples.75 This sensory profiling suggests that metabolic changes occur decades before motor symptoms appear, highlighting the need for early detection tools in both neurodegenerative and neuropsychiatric research.75 The integrative approach—combining metabolic evaluation, metabolic profiling, and lifestyle modification—offers a roadmap for psychedelic researchers seeking to move beyond simple symptomatic relief toward holistic disease modification.66

## **Legal and Regulatory Landscape as a Clinical Data Source**

The legalization of psychedelic services in Oregon and Colorado has created the world’s first state-regulated databases of supervised psilocybin use. Oregon’s Measure 109 and Colorado’s Proposition 122 distinguish themselves from medical models by not requiring a diagnosis for participation, thus providing data on the effects of psilocybin for spiritual growth, consciousness exploration, and creativity.78 These ecosystems are essential for understanding the "safety in the wild" of psychedelic substances when administered under trained supervision.81

Legal cases have also become vital sources of clinical information. In Utah, the religious organization Singularism successfully challenged a police raid and mushroom seizure by arguing that psilocybin is a sacramental tool protected under the state’s Religious Freedom Restoration Act.83 The federal court ruling in this case acknowledged that modern entheogenic faiths may prioritize personal spiritual exploration over rigid dogma, effectively broadening the legal definition of religious practice.86

The Singularism case highlights a legal data point often overlooked in medical literature: the efficacy of the " scribe" model, where a facilitator records the voyager's insights during the ceremony to create "sacred scripture"—a form of real-time qualitative documentation that could be adapted for therapeutic integration.87 Furthermore, Judge Parrish noted the existence of a "double standard" in Utah, where psilocybin use is permitted at institutions like Intermountain Health for research but criminalized in religious settings.88 This tension underscores the need for a unified regulatory framework that applies constitutional protections equally to both secular and religious practitioners.91

| Legal / Regulatory Event | Impact on Data Collection | Key Clinical Context |
| :---- | :---- | :---- |
| **OR Measure 109** | Mandatory preparation/integration forms.92 | First statewide registry of non-diagnostic use.79 |
| **CO Prop 122** | Decriminalized personal use and healing centers.78 | Integration of legacy markets with assisted therapy.94 |
| **Singularism v. Utah** | Legal protection of psilocybin sacrament.85 | Validation of religious safety and screening protocols.85 |
| **UT SB200** | PSILOCYBIN medical provider registration.97 | State-authorized production and therapy providers.97 |
| **SB25-297 (CO)** | Mandated de-identified health outcome data.29 | Legislation focused on "stewardship" and risk reduction.29 |

The emerging legal framework in New Mexico and the development of "Coordinated Registry Networks" (CRNs) further illustrate the trend toward state-led data gathering.94 CRNs are proven mechanisms for amassing real-world evidence to support expanded safety evaluations in the post-approval period, fulfilling many medical safety requirements that traditional clinical trials cannot address.100

## **Molecular Informatics and Receptor Profile Analysis**

At the most granular level, psychedelic research relies on molecular informatics and radioligand binding assays to understand the "Affinity Binding" functionality of specific compounds. The National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP), directed by Dr. Bryan Roth, is the primary source for this high-resolution pharmacological data.101 This database provides Ki values (binding affinity) for hundreds of compounds across various 5-HT receptor subtypes, including 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C.56

| Receptor Subtype | Therapeutic / Biological Role | Clinical Significance in Psychedelic Data |
| :---- | :---- | :---- |
| **5-HT2A** | Primary target for hallucinogens.104 | Mediator of acute psychoactive and antidepressant effects.99 |
| **5-HT2B** | Expressed on heart valves.3 | Long-term agonist activity can induce cardiac valve stiffening.5 |
| **5-HT1A** | Regulation of mood and emotion.39 | High affinity in non-hallucinogenic antidepressant analogs.56 |
| **5-HT2C** | Modulation of anxiety and behavior.56 | Involved in the dysfunctional shifts observed in depression.56 |
| **Sigma-2 / SERT** | Neuroplasticity / Serotonin transport.55 | High affinity binding by ibogaine for SUD disruption.55 |

The integration of artificial intelligence into this domain has yielded groundbreaking results. Structure-based drug discovery now utilizes tools like AlphaFold2 (AF2) to predict low-energy receptor conformations, enabling the docking of billions of molecules against receptors like 5-HT2A.105 These AI campaigns have identified novel ligands with high affinities (e.g., Ki values \< 5 nM) that could serve as the basis for the next generation of non-hallucinogenic "psychoplastogens".62 By separating the "trip" from the therapeutic mechanism, researchers hope to improve the societal acceptance of psychedelic treatments while expanding their utility for patient populations that cannot tolerate intense psychoactive states.108

## **Ethical and Social Implications of Large-Scale Data Aggregation**

The transition toward a data-driven psychedelic renaissance is not without ethical complexities. The "psychedelic epiphany"—often characterized by feelings of "oceanic boundlessness" and the dissolution of the self—frequently conflicts with the self-interest and greed characteristic of free-market capitalism.78 Practitioners and advocates emphasize that access to these medicines should be broad, easy, and equitable, yet the costs of psychedelic-assisted sessions in legal settings currently average around $2,000, creating a significant barrier for many.78

Data stewardship involves more than just technical security; it requires the protection of participants from "hype" and the management of realistic expectations.22 The history of the "first wave" of psychedelic research in the 1960s serves as a warning of how sensationalism can derail scientific progress.22 Today, researchers are called upon to provide rigorous, detailed evidence to inform drug policy and legalization frameworks, ensuring that findings can be reproduced and applied optimally over time.22

A particularly sensitive area of data aggregation is the incorporation of knowledge from indigenous lineage carriers. There is a risk of "hegemony" in clinical models that attempt to eliminate legacy markets and all that has been learned through traditional ceremonial use.95 Ethical data practices must include proper credit to indigenous groups, their inclusion in decision-making processes, and equitable reimbursement for their contributions to scientific understanding.111

## **Technical Infrastructure and Security in Practitioner Networks**

The technical design of practitioner networks like the PPN reflects a deep concern for liability and regulatory compliance. The "Audit Logs" screen in these systems is a critical tool for practitioners, providing a forensics-grade history of every click, dose change, and outcome.39 In the event of an FDA or IRB audit, practitioners can export these records (often in Parquet format) to prove their adherence to safety protocols.39

The "Interaction Checker" and "Neural Copilot" are active participants in clinical safety, functioning as a "safety partner" that warns practitioners about potential drug-drug conflicts before sessions begin.39 This technology addresses the widespread anxiety among clinicians regarding medication conflicts, such as the risk of serotonin syndrome or reduced efficacy in patients on long-term SSRI protocols.39

| Technical Specification | Implementation Method | Clinical Advantage |
| :---- | :---- | :---- |
| **Local-First Privacy** | On-device encryption of PII.39 | Zero possibility of central data breach exposing patient names.39 |
| **Cryptographic Hashing** | Immutable log of session metadata.39 | Forensic proof of protocol adherence for licensing boards.39 |
| **Cross-Reference Engine** | AI matching of community and public data.39 | Real-time discovery of novel safety signals in the field.39 |
| **Automated ID System** | Random, unique patient identifiers.39 | Longitudinal tracking without compromising HIPAA.13 |
| **Dynamic Scaling** | Neural engine protocol searches.39 | Rapid adaptation of doses based on participant demographics.39 |

The evolution toward a "post-market" landscape for psychedelics demands innovative surveillance systems that proactively monitor utilization by both providers and patients.2 Incorrect conclusions, such as misattributing adverse events to illicit use versus controlled therapeutic use, can only be avoided through intentionally designed "mosaic" data systems.2 These systems must incorporate diverse domains—including street price information, web discussion patterns (e.g., from Erowid or Bluelight), and poison center data—to provide a truly comprehensive understanding of the safety and effectiveness of new psychedelic medications.1

## **Advanced Analytical Frameworks for Qualitative and Mixed Methods**

The analysis of psychedelic therapy data frequently requires the use of qualitative or mixed-methods approaches to capture the richness of the subjective experience. Tools like Dedoose are used for the thematic analysis of interviews and focus groups, allowing researchers to explore broad narratives such as "psychedelic microdosing as a self-help technology" or "microdosing as a technology of slow living".117 These qualitative insights often provide the "why" behind quantitative data points, revealing participant motivations and perceived benefits that standardized scales might miss.117

Field data collection—gathering firsthand information in natural environments—is a vital counterpart to office-based or laboratory settings.120 This approach enables researchers to observe behaviors and nuanced social dynamics as they occur in real life, bridging the gap between theoretical frameworks and practical therapeutic outcomes.121 In the context of the Ibogaine Patient Survey, this qualitative focus has been essential for documenting the role of "meaning-making" in trauma processing, an area where Veterans describe ibogaine as the first treatment that allowed them to confront trauma without being overwhelmed.63

| Analytical Method | Research Application | Specific Clinical Insight |
| :---- | :---- | :---- |
| **Thematic Analysis** | Qualitative interview coding.117 | Identifies barriers to engagement for BIPOC therapists.118 |
| **Mixed Methods** | Combining BDI/MADRS with reflections.28 | Correlates reduced rumination with increased positive refocusing.123 |
| **Ecological Assessment** | Real-time mood/sleep tracking.124 | Reveals discrepancies between moment-to-moment and retrospective reports.124 |
| **Delphi Survey** | Expert consensus building.125 | Establishes field perspectives on RWE standards for medical cannabis.125 |
| **Meta-Analysis** | Living Systematic Reviews (SYPRES).126 | Continuously updates the repository of psilocybin efficacy findings.126 |

The current research trajectory suggests that "stratified psychiatry"—incorporating biomarkers and neuroimaging into clinical decision-making—will become the gold standard.127 By identifying neurobiological profiles that predict a patient's response to specific agents, clinicians can move toward a more personalized approach that optimizes both efficacy and safety.127 This requires the seamless integration of institutional databases (e.g., the Allen Institute's ABC Atlas) with clinical outcome registries to "crack the code" on complex neurodegenerative and psychiatric conditions.129

## **Conclusion: Synthesis of Global Psychedelic Intelligence**

The analysis of all available data sources—from the rigorous chemistry standards of the FDA to the narrative experience reports of grassroots microdosers—reveals a field that is rapidly professionalizing while grappling with its unconventional origins. The synthesis of institutional data (CDISC/REDCap) with real-world evidence platforms (Osmind/Althea) and decentralized wisdom trusts (PPN) is creating a uniquely robust repository of knowledge. While challenges such as functional unblinding and the placebo effect in microdosing remain significant analytical hurdles, the move toward transdiagnostic studies, adaptive trial designs, and AI-driven structure-based drug discovery indicates a promising future.

Stakeholders must prioritize the creation of a transparent, accountable, and culturally sensitive data care system. This involves not only technical innovation in zero-knowledge security and neural copilots but also a commitment to stewardship that honors both scientific rigor and the profound, transformative potential of the psychedelic experience. As the field matures, the ability to distinguish meaningful clinical signals from the noise of public discourse will be the defining factor in establishing psychedelic-assisted therapy as a cornerstone of 21st-century mental healthcare.22

#### **Works cited**

1. Psychedelic Studies \- | RMPDS, accessed January 29, 2026, [https://www.rmpds.org/node](https://www.rmpds.org/node)  
2. Optimizing Real-World Benefit and Risk of New Psychedelic ... \- Scribd, accessed January 29, 2026, [https://www.scribd.com/document/735865131/Optimizing-Real-world-Benefit-and-Risk-of-New-Psychedelic-Medications-The-Need-for-Innovative-Postmarket-Surveillance](https://www.scribd.com/document/735865131/Optimizing-Real-world-Benefit-and-Risk-of-New-Psychedelic-Medications-The-Need-for-Innovative-Postmarket-Surveillance)  
3. Psychedelic Drugs: Considerations for Clinical Investigations \- FDA, accessed January 29, 2026, [https://www.fda.gov/media/169694/download](https://www.fda.gov/media/169694/download)  
4. FDA Issues First Draft Guidance on Clinical Trials with Psychedelic ..., accessed January 29, 2026, [https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs](https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs)  
5. Unpacking FDA's Draft Guidance on Psychedelic Research, accessed January 29, 2026, [https://www.precisionformedicine.com/blog/unpacking-fdas-draft-guidance-on-psychedelic-research-for-clinical-success/](https://www.precisionformedicine.com/blog/unpacking-fdas-draft-guidance-on-psychedelic-research-for-clinical-success/)  
6. Psychedelic Drug Development: FDA Guidance \- MMS Holdings, accessed January 29, 2026, [https://mmsholdings.com/perspectives/psychedelic-drug-development/](https://mmsholdings.com/perspectives/psychedelic-drug-development/)  
7. FDA Draft Guidance on Clinical Trials for Psychedelics, accessed January 29, 2026, [https://phillipslytle.com/fda-draft-guidance-on-clinical-trials-for-psychedelics/](https://phillipslytle.com/fda-draft-guidance-on-clinical-trials-for-psychedelics/)  
8. Study Data Standards Resources \- FDA, accessed January 29, 2026, [https://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-resources](https://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-resources)  
9. A Guide to CDISC Standards Used in Clinical Research \- Certara, accessed January 29, 2026, [https://www.certara.com/blog/a-guide-to-cdisc-standards-used-in-clinical-research/](https://www.certara.com/blog/a-guide-to-cdisc-standards-used-in-clinical-research/)  
10. List of Biotech, Pharmaceutical & Life Sciences companies in New ..., accessed January 29, 2026, [https://app.biopharmiq.com/company-lists-all/list-of-biotech-pharmaceutical-life-sciences-companies-in-new-york](https://app.biopharmiq.com/company-lists-all/list-of-biotech-pharmaceutical-life-sciences-companies-in-new-york)  
11. A Comprehensive Guide to REDCap, accessed January 29, 2026, [https://www.unmc.edu/vcr/\_documents/unmc\_redcap\_usage.pdf](https://www.unmc.edu/vcr/_documents/unmc_redcap_usage.pdf)  
12. (PDF) Use of research electronic data capture (REDCap) in a ..., accessed January 29, 2026, [https://www.researchgate.net/publication/372162180\_Use\_of\_research\_electronic\_data\_capture\_REDCap\_in\_a\_sequential\_multiple\_assignment\_randomized\_trial\_SMART\_a\_practical\_example\_of\_automating\_double\_randomization](https://www.researchgate.net/publication/372162180_Use_of_research_electronic_data_capture_REDCap_in_a_sequential_multiple_assignment_randomized_trial_SMART_a_practical_example_of_automating_double_randomization)  
13. Penn Medicine REDCap | Penn Medicine Clinical Research, accessed January 29, 2026, [https://www.med.upenn.edu/clinicalresearch/redcap.html](https://www.med.upenn.edu/clinicalresearch/redcap.html)  
14. REDCap, accessed January 29, 2026, [https://project-redcap.org/](https://project-redcap.org/)  
15. mctc195\_template\_data-management-plan.docx \- Metis, accessed January 29, 2026, [https://metis.melbournechildrens.com/media/1nqd5r2x/mctc195\_template\_data-management-plan.docx](https://metis.melbournechildrens.com/media/1nqd5r2x/mctc195_template_data-management-plan.docx)  
16. Investigator's Brochure, accessed January 29, 2026, [https://maps.org/wp-content/uploads/2013/11/MDMAIB12thEditionFinal17AUG2020.pdf](https://maps.org/wp-content/uploads/2013/11/MDMAIB12thEditionFinal17AUG2020.pdf)  
17. NCT05259943 | Microdosing Psychedelics to Improve Mood, accessed January 29, 2026, [https://clinicaltrials.gov/study/NCT05259943](https://clinicaltrials.gov/study/NCT05259943)  
18. From Efficacy to Effectiveness: Evaluating Psychedelic Randomized ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11997373/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997373/)  
19. Advancing Psychedelic Clinical Study Design, accessed January 29, 2026, [https://reaganudall.org/sites/default/files/2024-06/Advancing%20Psychedelic%20Clinical%20Study%20Design\_Meeting%20Summary%20%281%29.pdf](https://reaganudall.org/sites/default/files/2024-06/Advancing%20Psychedelic%20Clinical%20Study%20Design_Meeting%20Summary%20%281%29.pdf)  
20. EMA multi-stakeholder workshop on psychedelics, accessed January 29, 2026, [https://www.ema.europa.eu/en/documents/report/report-ema-multi-stakeholder-workshop-psychedelics\_en.pdf](https://www.ema.europa.eu/en/documents/report/report-ema-multi-stakeholder-workshop-psychedelics_en.pdf)  
21. Psychedelic Clinical Trials: Regulatory Considerations from the FDA, accessed January 29, 2026, [https://www.nationalacademies.org/cdn/materials/9fba0f83-6e86-4852-8149-63c3ad54e433](https://www.nationalacademies.org/cdn/materials/9fba0f83-6e86-4852-8149-63c3ad54e433)  
22. Therapeutic setting as an essential component of psychedelic ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9668859/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9668859/)  
23. New Partnership Expands Access to Psychedelic Therapy for Those ..., accessed January 29, 2026, [https://withalthea.com/2025/12/02/forward-fund-thank-you-life/](https://withalthea.com/2025/12/02/forward-fund-thank-you-life/)  
24. Top 5 EHR Features for Evolving Psychedelic Practices \- YouTube, accessed January 29, 2026, [https://www.youtube.com/watch?v=RcnPS6L-GrE](https://www.youtube.com/watch?v=RcnPS6L-GrE)  
25. Psychedelic-Assisted Therapy | Leading Psychiatry and Ketamine ..., accessed January 29, 2026, [https://www.osmind.org/psychedelic-assisted-therapy](https://www.osmind.org/psychedelic-assisted-therapy)  
26. Nick von Christierson | CEO & Co-Founder, Woven Science, accessed January 29, 2026, [https://www.psychedelicfinance.com/articles/nick-von-christierson-of-woven-science](https://www.psychedelicfinance.com/articles/nick-von-christierson-of-woven-science)  
27. Maya Health Raises $4.3 Million to Decentralize Psychedelic ..., accessed January 29, 2026, [https://www.prweb.com/releases/maya-health-raises-4-3-million-to-decentralize-psychedelic-medicine-research-879651200.html](https://www.prweb.com/releases/maya-health-raises-4-3-million-to-decentralize-psychedelic-medicine-research-879651200.html)  
28. Bendable Therapy and Osmind to Present First Real-World ..., accessed January 29, 2026, [https://www.businesswire.com/news/home/20250916874550/en/Bendable-Therapy-and-Osmind-to-Present-First-Real-World-Outcomes-Data-from-Legal-U.S.-Psilocybin-Services](https://www.businesswire.com/news/home/20250916874550/en/Bendable-Therapy-and-Osmind-to-Present-First-Real-World-Outcomes-Data-from-Legal-U.S.-Psilocybin-Services)  
29. What Colorado's New Data Collection Bill Means for Psychedelic ..., accessed January 29, 2026, [https://withalthea.com/2025/05/07/what-colorados-new-data-collection-bill-means-for-psychedelic-therapy/](https://withalthea.com/2025/05/07/what-colorados-new-data-collection-bill-means-for-psychedelic-therapy/)  
30. 2025 Psilocybin Outcomes Awards \- Althea, accessed January 29, 2026, [https://withalthea.com/psilocybin-outcomes-awards/](https://withalthea.com/psilocybin-outcomes-awards/)  
31. Facilitators \- Althea, accessed January 29, 2026, [https://withalthea.com/facilitators/](https://withalthea.com/facilitators/)  
32. Psychedelic Preparedness Scale \- Althea, accessed January 29, 2026, [https://withalthea.com/psychedelic-preparedness-scale/](https://withalthea.com/psychedelic-preparedness-scale/)  
33. Althea \- Psychedelic Care Navigation \- Althea, accessed January 29, 2026, [https://withalthea.com/](https://withalthea.com/)  
34. Discover 20 Real World Evidence Startups to Watch (2025), accessed January 29, 2026, [https://www.startus-insights.com/innovators-guide/real-world-evidence-startups/](https://www.startus-insights.com/innovators-guide/real-world-evidence-startups/)  
35. Transdiagnostic Outcomes from Yale's Real-World Psilocybin Trial, accessed January 29, 2026, [https://virtualtrip.maps.org/video/transdiagnostic-outcomes-from-yales-real-world-psilocybin-trial-connecticut-funded-pioneering-psychedelic-therapy-program-and-insights-from-other-state-initiatives/](https://virtualtrip.maps.org/video/transdiagnostic-outcomes-from-yales-real-world-psilocybin-trial-connecticut-funded-pioneering-psychedelic-therapy-program-and-insights-from-other-state-initiatives/)  
36. Real-World Psilocybin Therapy for Treatment-Resistant Depression, accessed January 29, 2026, [https://www.researchgate.net/publication/398543699\_Real-World\_Psilocybin\_Therapy\_for\_Treatment-Resistant\_Depression\_a\_Retrospective\_Observational\_Study](https://www.researchgate.net/publication/398543699_Real-World_Psilocybin_Therapy_for_Treatment-Resistant_Depression_a_Retrospective_Observational_Study)  
37. The value of real world evidence: The case of medical cannabis, accessed January 29, 2026, [https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1027159/full](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1027159/full)  
38. Is it now time to prepare psychiatry for a psychedelic future?, accessed January 29, 2026, [https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/is-it-now-time-to-prepare-psychiatry-for-a-psychedelic-future/9A451B79A6B250BEA45BEE2243596FCB](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/is-it-now-time-to-prepare-psychiatry-for-a-psychedelic-future/9A451B79A6B250BEA45BEE2243596FCB)  
39. PPN Meeting Notes \- Anonymized  
40. On the Menu: Nutrition and Parkinson's disease \- Day 1 \- YouTube, accessed January 29, 2026, [https://www.youtube.com/watch?v=DHylAb\_OZRA](https://www.youtube.com/watch?v=DHylAb_OZRA)  
41. Microdose Research by Dr James Fadiman \- Psychedelic Press, accessed January 29, 2026, [https://psychedelicpress.co.uk/blogs/psychedelic-press-blog/microdose-research-james-fadiman](https://psychedelicpress.co.uk/blogs/psychedelic-press-blog/microdose-research-james-fadiman)  
42. Lynn Marie:​Hello and welcome to a very special episode of the ..., accessed January 29, 2026, [https://static1.squarespace.com/static/5d28f73b41951900011c98ad/t/5f3c1942343aa768cfeeb287/1597774147385/James+Fadiman+Episode.pdf](https://static1.squarespace.com/static/5d28f73b41951900011c98ad/t/5f3c1942343aa768cfeeb287/1597774147385/James+Fadiman+Episode.pdf)  
43. James Fadiman's lab | Sofia University \- ResearchGate, accessed January 29, 2026, [https://www.researchgate.net/lab/James-Fadiman-Lab](https://www.researchgate.net/lab/James-Fadiman-Lab)  
44. Microdose research: without approvals, control groups, double ..., accessed January 29, 2026, [https://www.researchgate.net/publication/308138461\_Microdose\_research\_without\_approvals\_control\_groups\_double\_blinds\_staff\_or\_funding](https://www.researchgate.net/publication/308138461_Microdose_research_without_approvals_control_groups_double_blinds_staff_or_funding)  
45. Microdose.me, accessed January 29, 2026, [https://microdose.me/](https://microdose.me/)  
46. Health Archives | Psychedelics Today, accessed January 29, 2026, [https://psychedelicstoday.com/post\_tags/health/](https://psychedelicstoday.com/post_tags/health/)  
47. Self-blinding citizen science to explore psychedelic microdosing, accessed January 29, 2026, [https://elifesciences.org/articles/62878/figures](https://elifesciences.org/articles/62878/figures)  
48. Self-blinding citizen science to explore psychedelic microdosing | eLife, accessed January 29, 2026, [https://elifesciences.org/articles/62878](https://elifesciences.org/articles/62878)  
49. (PDF) Self-blinding citizen science to explore psychedelic microdosing, accessed January 29, 2026, [https://www.researchgate.net/publication/351087764\_Self-blinding\_citizen\_science\_to\_explore\_psychedelic\_microdosing](https://www.researchgate.net/publication/351087764_Self-blinding_citizen_science_to_explore_psychedelic_microdosing)  
50. Self-blinding citizen science to explore psychedelic microdosing \- NIH, accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7925122/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7925122/)  
51. Be Part of the Solution: How Your Experience Can Help Ibogaine ..., accessed January 29, 2026, [https://serenityprofessionalcounseling.com/be-part-of-the-solution-how-your-experience-can-help-ibogaine-research](https://serenityprofessionalcounseling.com/be-part-of-the-solution-how-your-experience-can-help-ibogaine-research)  
52. Ibogaine Patient Survey, accessed January 29, 2026, [https://ibogainepatientsurvey.org/](https://ibogainepatientsurvey.org/)  
53. The Ohio State University Launches Groundbreaking Global Survey ..., accessed January 29, 2026, [https://www.prnob.com/release/show/the-ohio-state-university-launches-groundbreaking-global-survey-on-ibogaine-treatment-outcomes/490511](https://www.prnob.com/release/show/the-ohio-state-university-launches-groundbreaking-global-survey-on-ibogaine-treatment-outcomes/490511)  
54. Subjective effectiveness of ibogaine treatment for problematic opioid ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6157925/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6157925/)  
55. (PDF) A systematic literature review of clinical trials and therapeutic ..., accessed January 29, 2026, [https://www.researchgate.net/publication/357437011\_A\_systematic\_literature\_review\_of\_clinical\_trials\_and\_therapeutic\_applications\_of\_ibogaine](https://www.researchgate.net/publication/357437011_A_systematic_literature_review_of_clinical_trials_and_therapeutic_applications_of_ibogaine)  
56. Three Naturally-Occurring Psychedelics and Their Significance in ..., accessed January 29, 2026, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.927984/pdf](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.927984/pdf)  
57. Psychoactive drug ibogaine effectively treats traumatic brain injury in ..., accessed January 29, 2026, [https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html](https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html)  
58. The emergence of psychedelics as medicine, accessed January 29, 2026, [https://www.apa.org/monitor/2024/06/psychedelics-as-medicine](https://www.apa.org/monitor/2024/06/psychedelics-as-medicine)  
59. Small Preliminary Trial of Psychoactive Drug Ibogaine Yields 'Initial ..., accessed January 29, 2026, [https://bbrfoundation.org/content/small-preliminary-trial-psychoactive-drug-ibogaine-yields-initial-evidence-powerful](https://bbrfoundation.org/content/small-preliminary-trial-psychoactive-drug-ibogaine-yields-initial-evidence-powerful)  
60. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers ..., accessed January 29, 2026, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00529/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00529/full)  
61. Center for Psychedelic Drug Research and Education, accessed January 29, 2026, [https://www.cpdre.org/projects](https://www.cpdre.org/projects)  
62. Psychedelic-Inspired Approaches for Treating Neurodegenerative ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9126991/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9126991/)  
63. Seeking Real-World Voices: The Global Ibogaine Patient Survey, accessed January 29, 2026, [https://maps.org/news/bulletin/seeking-real-world-voices/](https://maps.org/news/bulletin/seeking-real-world-voices/)  
64. The Ohio State University Launches First Global Survey to Study ..., accessed January 29, 2026, [https://www.prweb.com/releases/the-ohio-state-university-launches-first-global-survey-to-study-ibogaine-treatment-outcomes-302429426.html](https://www.prweb.com/releases/the-ohio-state-university-launches-first-global-survey-to-study-ibogaine-treatment-outcomes-302429426.html)  
65. Dr Laurie Mischley \- PD Warrior, accessed January 29, 2026, [https://pdwarrior.com/speaker/laurie-mischley-2025/](https://pdwarrior.com/speaker/laurie-mischley-2025/)  
66. Laurie Mischley, ND PhD MPH \- Parkinson's Foundation, accessed January 29, 2026, [https://www.parkinson.org/sites/default/files/documents/Mischley\_Slides\_2022.pdf](https://www.parkinson.org/sites/default/files/documents/Mischley_Slides_2022.pdf)  
67. NUTRITION | Dirty dozen & clean fifteen, accessed January 29, 2026, [https://youngonsetparkinsons.org.au/resources/nutrition-dirty-dozen-and-clean-fifteen/](https://youngonsetparkinsons.org.au/resources/nutrition-dirty-dozen-and-clean-fifteen/)  
68. PRO-PD, accessed January 29, 2026, [https://educationismedicine.com/pro-pd](https://educationismedicine.com/pro-pd)  
69. LAURIE MISCHLEY, ND, PhD, MPH \- Seattle Integrative Medicine, accessed January 29, 2026, [https://seattleintegrativemedicine.com/project/laurie-mischley/](https://seattleintegrativemedicine.com/project/laurie-mischley/)  
70. Rebranding" Parkinson's \- by Dr Laurie Mischley \- YouTube, accessed January 29, 2026, [https://www.youtube.com/watch?v=E6c2iPBXVow](https://www.youtube.com/watch?v=E6c2iPBXVow)  
71. Using the PRO-21 Diet to Slow Parkinson's Progression \- YouTube, accessed January 29, 2026, [https://www.youtube.com/watch?v=VTp5GJSEAFI](https://www.youtube.com/watch?v=VTp5GJSEAFI)  
72. Strength in Connections \- American Parkinson Disease Association, accessed January 29, 2026, [https://www.apdaparkinson.org/wp-content/uploads/2025/07/ParkinsonPathfinder\_Summer25-V5\_Spreads.pdf](https://www.apdaparkinson.org/wp-content/uploads/2025/07/ParkinsonPathfinder_Summer25-V5_Spreads.pdf)  
73. Everything You Need to Know About Caregiving for Parkinson's ..., accessed January 29, 2026, [https://dokumen.pub/download/everything-you-need-to-know-about-caregiving-for-parkinsons-disease-9781557539960.html](https://dokumen.pub/download/everything-you-need-to-know-about-caregiving-for-parkinsons-disease-9781557539960.html)  
74. Lifestyle Modification for Parkinson's Disease \- Jefferson Healthcare, accessed January 29, 2026, [https://jeffersonhealthcare.org/wp-content/uploads/2025/01/PD-Mischley-011325.pdf](https://jeffersonhealthcare.org/wp-content/uploads/2025/01/PD-Mischley-011325.pdf)  
75. Parkinson's, Detection \- Dr. Laurie K Mischley, accessed January 29, 2026, [https://educationismedicine.com/early-detection](https://educationismedicine.com/early-detection)  
76. Laurie Mischley, accessed January 29, 2026, [https://lauriemischley.com/](https://lauriemischley.com/)  
77. Dr Laurie Mischley \- PD Warrior, accessed January 29, 2026, [https://pdwarrior.com/speaker/laurie-mischley/](https://pdwarrior.com/speaker/laurie-mischley/)  
78. Insights from the Boulder Startup Week Panel \- Althea, accessed January 29, 2026, [https://withalthea.com/2025/05/20/psychedelics-and-entrepreneurship-insights-from-the-boulder-startup-week-panel/](https://withalthea.com/2025/05/20/psychedelics-and-entrepreneurship-insights-from-the-boulder-startup-week-panel/)  
79. Psilocybin Therapy \- Althea, accessed January 29, 2026, [https://withalthea.com/psilocybin-therapy/](https://withalthea.com/psilocybin-therapy/)  
80. Psilocybin Therapy Archives \- Althea, accessed January 29, 2026, [https://withalthea.com/category/psilocybin-therapy/](https://withalthea.com/category/psilocybin-therapy/)  
81. About \- Althea \- Psychedelic Care Navigation, accessed January 29, 2026, [https://withalthea.com/about/](https://withalthea.com/about/)  
82. Psychedelic Therapy Information \- UC Berkeley BCSP, accessed January 29, 2026, [https://psychedelics.berkeley.edu/therapy/](https://psychedelics.berkeley.edu/therapy/)  
83. Season 2, Episode 10: Psychedelic Church vs. State of Utah (Pt. 1), accessed January 29, 2026, [https://psychedelics.berkeley.edu/season-2-episode-10-psychedelics-for-anorexia/](https://psychedelics.berkeley.edu/season-2-episode-10-psychedelics-for-anorexia/)  
84. What a Psychedelic Church Reveals about Religion and the Law, accessed January 29, 2026, [https://petrieflom.law.harvard.edu/2025/11/28/what-a-psychedelic-church-reveals-about-religion-and-the-law/](https://petrieflom.law.harvard.edu/2025/11/28/what-a-psychedelic-church-reveals-about-religion-and-the-law/)  
85. JENSEN v. UTAH COUNTY (2025) \- FindLaw Caselaw, accessed January 29, 2026, [https://caselaw.findlaw.com/court/us-dis-crt-d-uta/116998560.html](https://caselaw.findlaw.com/court/us-dis-crt-d-uta/116998560.html)  
86. Discover Singularism: A Legal, Safe, and Effective Path to ..., accessed January 29, 2026, [https://singularism.org/](https://singularism.org/)  
87. Psilocybin Archives \- Reason Magazine, accessed January 29, 2026, [https://reason.com/tag/psilocybin/feed/atom/](https://reason.com/tag/psilocybin/feed/atom/)  
88. This Week in Psychedelics \- Tricycle Day, accessed January 29, 2026, [https://www.tricycleday.com/p/psilocybin-for-all](https://www.tricycleday.com/p/psilocybin-for-all)  
89. Breaking News on Psychedelics, Psilocybin Therapy, and Religious ..., accessed January 29, 2026, [https://singularism.org/blog/press-release-lawsuit-start](https://singularism.org/blog/press-release-lawsuit-start)  
90. Sacred Spores: Utah's Mushroom Case Sends a Message, accessed January 29, 2026, [https://saltbakedcity.com/sacred-spores-utahs-mushroom-case-sends-a-message/](https://saltbakedcity.com/sacred-spores-utahs-mushroom-case-sends-a-message/)  
91. Georgia religious freedom bill in House; judge applies Utah law to ..., accessed January 29, 2026, [https://www.baptistpress.com/resource-library/news/georgia-religious-freedom-bill-in-house-judge-applies-utah-law-to-mushroom-use/](https://www.baptistpress.com/resource-library/news/georgia-religious-freedom-bill-in-house-judge-applies-utah-law-to-mushroom-use/)  
92. Access Psilocybin Services : Prevention and Wellness \- Oregon.gov, accessed January 29, 2026, [https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-access-psilocybin-services.aspx](https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-access-psilocybin-services.aspx)  
93. Guided Psychedelic Therapy Oregon, accessed January 29, 2026, [https://ftp.fosswaterwayseaport.org/browse/YdZ9br/9GF304/guided-psychedelic\_therapy\_oregon.pdf](https://ftp.fosswaterwayseaport.org/browse/YdZ9br/9GF304/guided-psychedelic_therapy_oregon.pdf)  
94. Are Magic Mushrooms Legal in the US? \- Althea, accessed January 29, 2026, [https://withalthea.com/2025/01/20/are-magic-mushrooms-legal-in-the-us/](https://withalthea.com/2025/01/20/are-magic-mushrooms-legal-in-the-us/)  
95. exploring the ethical and practical considerations of psychedelics ..., accessed January 29, 2026, [https://www.hhs.gov/sites/default/files/oew-program-book-2023.pdf](https://www.hhs.gov/sites/default/files/oew-program-book-2023.pdf)  
96. Psilocybin Mushrooms in Religious Ceremonies Upheld by Utah Court, accessed January 29, 2026, [https://ayaadvisors.org/psilocybin-mushrooms-in-religious-ceremonies-upheld-by-utah-court/](https://ayaadvisors.org/psilocybin-mushrooms-in-religious-ceremonies-upheld-by-utah-court/)  
97. SB0200 \- Utah Legislature, accessed January 29, 2026, [https://le.utah.gov/\~2023/bills/static/SB0200.html](https://le.utah.gov/~2023/bills/static/SB0200.html)  
98. Stories, Insights, and Updates on Psychedelics ... \- Singularism Blog, accessed January 29, 2026, [https://singularism.org/blog](https://singularism.org/blog)  
99. How Does Psilocybin Work to Treat Depression? \- Althea, accessed January 29, 2026, [https://withalthea.com/2025/01/27/how-does-psilocybin-work-to-treat-depression/](https://withalthea.com/2025/01/27/how-does-psilocybin-work-to-treat-depression/)  
100. Policy considerations that support equitable access to responsible ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9536012/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9536012/)  
101. Chemocentric Informatics Approach to Drug Discovery: Identification ..., accessed January 29, 2026, [https://2024.sci-hub.se/1148/408a959d1e6cbc40ad08b3e47d53efac/hajjo2012.pdf](https://2024.sci-hub.se/1148/408a959d1e6cbc40ad08b3e47d53efac/hajjo2012.pdf)  
102. Structure–Activity Relationships for Psilocybin, Baeocystin ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9667540/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9667540/)  
103. Structure–Activity Relationships for Psilocybin, Baeocystin ..., accessed January 29, 2026, [https://pubs.acs.org/doi/10.1021/acsptsci.2c00177](https://pubs.acs.org/doi/10.1021/acsptsci.2c00177)  
104. Dr. Robin Carhart-Harris: The Science of Psychedelics for..., accessed January 29, 2026, [https://www.researchhub.com/post/964/dr-robin-carhart-harris-the-science-of-psychedelics-for-mental-health-huberman-lab-podcast](https://www.researchhub.com/post/964/dr-robin-carhart-harris-the-science-of-psychedelics-for-mental-health-huberman-lab-podcast)  
105. 1 Molecular insights into the modulation of the 5HT2A receptor by ..., accessed January 29, 2026, [https://www.biorxiv.org/content/10.1101/2024.07.23.604750v1.full.pdf](https://www.biorxiv.org/content/10.1101/2024.07.23.604750v1.full.pdf)  
106. TABLE 2 Binding affinity (pK i ) for 5-HT receptors \- ResearchGate, accessed January 29, 2026, [https://www.researchgate.net/figure/Binding-affinity-pK-i-for-5-HT-receptors\_tbl1\_13590210](https://www.researchgate.net/figure/Binding-affinity-pK-i-for-5-HT-receptors_tbl1_13590210)  
107. AlphaFold2 structures guide prospective ligand discovery, accessed January 29, 2026, [https://thealonlab.org/papers/science.adn6354.pdf](https://thealonlab.org/papers/science.adn6354.pdf)  
108. Investigating the role microdosing psychedelics could have in ... \- DiVA, accessed January 29, 2026, [https://umu.diva-portal.org/smash/get/diva2:1591013/FULLTEXT02.pdf](https://umu.diva-portal.org/smash/get/diva2:1591013/FULLTEXT02.pdf)  
109. Psychedelic mushroom interest grows in Utah with center opening in ..., accessed January 29, 2026, [https://ecfes.net/spirituality/psychedelic-mushroom-interest-grows-in-utah-with-center-opening-in-provo/](https://ecfes.net/spirituality/psychedelic-mushroom-interest-grows-in-utah-with-center-opening-in-provo/)  
110. NIH & FDA Psychedelic Research Letter \- Brian Schatz, accessed January 29, 2026, [https://www.schatz.senate.gov/download/nih-and-fda-psychedelic-research-letter?download=1](https://www.schatz.senate.gov/download/nih-and-fda-psychedelic-research-letter?download=1)  
111. Current U.S. Approaches to Studying Psychedelic Medicines ..., accessed January 29, 2026, [https://www.researchgate.net/publication/390093105\_Current\_US\_Approaches\_to\_Studying\_Psychedelic\_Medicines\_Compared\_to\_Psychedelics\_Use\_Among\_Indigenous\_Groups\_What\_Are\_We\_Missing](https://www.researchgate.net/publication/390093105_Current_US_Approaches_to_Studying_Psychedelic_Medicines_Compared_to_Psychedelics_Use_Among_Indigenous_Groups_What_Are_We_Missing)  
112. How important is preparation really? \- Althea \- Althea \- Psychedelic ..., accessed January 29, 2026, [https://withalthea.com/2025/11/03/how-important-is-preparation-really/](https://withalthea.com/2025/11/03/how-important-is-preparation-really/)  
113. REDCap: A Tool for the Electronic Capture of Research Data, accessed January 29, 2026, [https://www.researchgate.net/publication/311930707\_REDCap\_A\_Tool\_for\_the\_Electronic\_Capture\_of\_Research\_Data](https://www.researchgate.net/publication/311930707_REDCap_A_Tool_for_the_Electronic_Capture_of_Research_Data)  
114. FDA Issues First Draft Guidance on Clinical Trials with Psychedelic ..., accessed January 29, 2026, [https://www.gmp-compliance.org/gmp-news/fda-issues-first-draft-guidance-on-clinical-trials-with-psychedelic-drugs](https://www.gmp-compliance.org/gmp-news/fda-issues-first-draft-guidance-on-clinical-trials-with-psychedelic-drugs)  
115. Effects and Toxicity of Hallucinogenic New Psychoactive ..., accessed January 29, 2026, [https://researchonline.ljmu.ac.uk/id/eprint/24715/1/Effects%20and%20Toxicity%20of%20Hallucinogenic%20New%20Psychoactive%20Substances%20From%20the%20Perspectives%20of%20e-Psychonauts.pdf](https://researchonline.ljmu.ac.uk/id/eprint/24715/1/Effects%20and%20Toxicity%20of%20Hallucinogenic%20New%20Psychoactive%20Substances%20From%20the%20Perspectives%20of%20e-Psychonauts.pdf)  
116. arXiv:2201.13064v1 \[cs.SI\] 31 Jan 2022, accessed January 29, 2026, [https://arxiv.org/pdf/2201.13064](https://arxiv.org/pdf/2201.13064)  
117. a Typology of Modes of Uses of Psychedelic Microdosing Student, accessed January 29, 2026, [https://thesis.eur.nl/pub/56253/Grusauskaite-Kamile.pdf](https://thesis.eur.nl/pub/56253/Grusauskaite-Kamile.pdf)  
118. A qualitative study in: Journal of Psychedelic StudiesOnline First, accessed January 29, 2026, [https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2025.00460/article-10.1556-2054.2025.00460.xml](https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2025.00460/article-10.1556-2054.2025.00460.xml)  
119. Collecting and Analyzing Qualitative Data | Field Epi Manual \- CDC, accessed January 29, 2026, [https://www.cdc.gov/field-epi-manual/php/chapters/qualitative-data.html](https://www.cdc.gov/field-epi-manual/php/chapters/qualitative-data.html)  
120. Field Data Collection | Research Starters \- EBSCO, accessed January 29, 2026, [https://www.ebsco.com/research-starters/sociology/field-data-collection](https://www.ebsco.com/research-starters/sociology/field-data-collection)  
121. Field Research: Definition, Methods, and Real-World Applications, accessed January 29, 2026, [https://www.voxco.com/resources/field-research](https://www.voxco.com/resources/field-research)  
122. What is field data collection? Methods and use cases, accessed January 29, 2026, [https://felt.com/blog/field-data-collection](https://felt.com/blog/field-data-collection)  
123. Real-World Effectiveness and Safety of Psychedelic-Assisted ..., accessed January 29, 2026, [https://www.medrxiv.org/content/10.1101/2025.12.01.25341335v1](https://www.medrxiv.org/content/10.1101/2025.12.01.25341335v1)  
124. Salience, sensemaking, and setting in psilocybin microdosing, accessed January 29, 2026, [https://www.tandfonline.com/doi/full/10.1080/09515089.2024.2393690](https://www.tandfonline.com/doi/full/10.1080/09515089.2024.2393690)  
125. Scientific publications | European Medicines Agency (EMA), accessed January 29, 2026, [https://www.ema.europa.eu/en/news-and-events/publications/scientific-publications](https://www.ema.europa.eu/en/news-and-events/publications/scientific-publications)  
126. Psychedelics-Assisted Treatments | SYPRES \- Metapsy, accessed January 29, 2026, [https://www.metapsy.org/sypres/](https://www.metapsy.org/sypres/)  
127. Psilocybin in the real world: Regulatory, ethical, and operational ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12831811/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12831811/)  
128. A review of psychedelics trials completed in depression, informed by ..., accessed January 29, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12244136/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244136/)  
129. A new view of Parkinson's disease \- Allen Institute, accessed January 29, 2026, [https://alleninstitute.org/news/a-new-view-of-parkinsons-data/](https://alleninstitute.org/news/a-new-view-of-parkinsons-data/)  
130. Expanded Research Tool to Crack the Code on Parkinson's, the ..., accessed January 29, 2026, [https://parkinsonsroadmap.org/news/expanded-research-tool-to-crack-the-code-on-parkinsons-the-fastest-growing-neurodegenerative-disease/](https://parkinsonsroadmap.org/news/expanded-research-tool-to-crack-the-code-on-parkinsons-the-fastest-growing-neurodegenerative-disease/)

# **What do people say are the most valuable parts of the data?**

Stakeholders in the psychedelic therapy field identify several components of data as uniquely valuable, often emphasizing the "mosaic" of information required to bridge the gap between academic trials and naturalistic clinical practice.

### **Real-World Evidence (RWE) and the "Patient Journey"**

Real-world evidence is considered high-value because it captures the "patient journey" beyond the narrow window of traditional clinical trials. This data is essential for understanding how treatments perform in diverse populations, including those with complex comorbidities or those taking concomitant medications who are typically excluded from formal research. RWE provides greater "ecological validity" and temporal sensitivity, as it allows for ongoing longitudinal monitoring of thousands of patients rather than small, highly selected study groups.

\+1

### **Failure Data ("What Went Wrong")**

A significant "knowledge gap" exists because practitioners often report only successful outcomes, driven by ego or professional reputation. Capturing data on treatment failures, adverse reactions, and "what went wrong" is described as the "honey down the road" for the industry. This data acts as an early warning system that can identify issues like contaminated batches of medication or previously unknown drug-supplement interactions months before official regulatory warnings.

### **Subjective Patient-Reported Outcomes (PROs)**

Because the psychedelic experience is deeply personal, patient-perceived effectiveness is a critical data point. Valuable subjective metrics include:

* **Meaning-Making and Spiritual Insights:** These subjective elements are often relegated to footnotes in academic papers but are considered fundamental to long-term therapeutic success.  
* **Health-Related Quality of Life (HRQOL):** Measures such as the "presence of meaning" or "satisfaction with life" often carry more weight for patients and payors than simple symptom reduction scales.  
* **Functional Improvement:** Data on "return to work" and improved daily activity habits provide essential health economic evidence for insurance reimbursement.

### **Benchmarking and Collective Intelligence**

For individual practitioners, the most valuable part of aggregated data is the ability to benchmark their own clinical results against a "global hive mind". Accessing a "Tough Case Library" allows therapists to see what protocols succeeded for similar complex patients—such as high-anxiety non-responders—providing an evidence-based roadmap for difficult cases.

### **Molecular Informatics and Receptor Profiles**

At the pharmacological level, "Affinity Binding" data is highly valued by researchers seeking to develop the next generation of medicines. Detailed information on receptor subtypes, such as the role of 5-HT1A in regulating mood or 5-HT2B in heart safety, helps clinicians and drug developers identify "solution molecules" to observed clinical impediments.

